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Summary
Names influence how something is perceived. Diagnostic terms (diagnoses)
are the names of diseases that are usually derived either from some distinctive
characteristic of the disease or include an eponym recognizing someone who
elucidated the disease. No matter how logical and appropriate a name may be,
if it is not usable and used it is of no lasting value. This brief commentary
focuses on the nomenclature of systemic vasculitides, and uses as a prime
example Wegener’s granulomatosis, which has been renamed recently ‘granu-
lomatosis with polyangiitis’, in part because of concerns about the suitability
of Friedrich Wegener as the source of an eponym. The most distinctive patho-
logical feature of Wegener’s granulomatosis is multi-focal necrotizing inflam-
mation that has long been called granulomatosis. The systemic variant of
Wegener’s granulomatosis also is characterized by inflammation in many
different vessels or different types, i.e. polyangiitis. Thus, granulomatosis
with polyangiitis is a very appropriate alternative term for Wegener’s
granulomatosis. This term also is in accord with the name for a closely related
vasculitis, i.e. microscopic polyangiitis. Terms that indicate aetiology and
pathogenesis, when known, are useful to include in names for diseases
(diagnoses). Anti-neutrophil cytoplasmic autoantibodies specific for myelop-
eroxidase (MPO-ANCA) or proteinase 3 (PR3-ANCA) are implicated in the
cause of granulomatosis with polyangiitis and thus also should be specified in
the diagnosis (e.g. PR3-ANCA-positive granulomatosis with polyangiitis or
MPO-ANCA-positive microscopic polyangiitis). As our understanding of the
clinical manifestations, pathogenesis and aetiology of vasculitides change over
time, the names and approaches for diagnosing these diseases will change
accordingly.
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In Scene 2, Act II, of Shakespeare’s Romeo and Juliet, Juliet
asks: ‘What’s in a name? That which we call a rose by any
other name would smell as sweet.’ This states the fact that a
particular name does not alter the essential nature of what is
being named. However, Juliet also passionately laments that
Romeo’s family name is Montague and wishes that it could
‘be some other name’. This exemplifies how important a
name can be with respect to how something is perceived and
treated. In fact, the entire tragedy that befell Romeo and
Juliet was precipitated by perceptions and prejudices result-
ing from their names and classes. Names are not trivial.
In clinical practice and in biomedical research, the name
of a disease (i.e. the diagnostic term or diagnosis) derives
from prior knowledge of the disease and, importantly, may
drive future studies of the disease. Of necessity, a name
cannot contain all that is known about a disease but rather
should include words that at least conjure up some major
clinical or pathophysiological hallmark of the disease. Alter-
natively, especially if the pathophysiological nature of the
disease is unknown or poorly known, an eponym is used in
the diagnosis based on a seminal contribution by the source
of the name to the recognition or elucidation of the disease.
Names for diseases (diagnostic terms) often begin with rela-
tively arbitrary decisions by someone who is involved with
the clinical management or pathophysiological study of the
disease. Less often, and usually at a juncture when there is a
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perceived need to alter a commonly used name, a more
deliberative approach by a group of clinicians or scientists is
used to propose a change in nomenclature for a disease.
However, in the final analysis a name is useful only if it is
usable and used. No matter how logical and appropriate a
name may be based on contemporary knowledge of a
disease, if it is not usable and used it is of no lasting value. In
this brief commentary, as a case in point, I will focus on
Wegener’s granulomatosis (WG), recently renamed ‘granu-
lomatosis with polyangiitis’ (GPA) [1,2].
In spring 2011, just prior to the Fifteenth International
Vasculitis and ANCA Workshop, the deliberations of a
diverse group of clinicians and scientists will result in modi-
fications of the Chapel Hill Consensus Conference (CHCC)
nomenclature for systemic vasculitides, which will be based
on clinical, pathophysiological and ethical developments
since the original CHCC in 1993. The goals of the CHCC
were to reach consensus on the names for some of the most
common forms of systemic vasculitis and to construct root
definitions for these [3]. The success of this effort is evi-
denced by its wide adoption in both clinical and research
settings, and by greater than 17 000 citations in the medical
literature. An impact of the recommendations of the CHCC
is illustrated in Fig. 1, which shows the use of the diagnostic
terms ‘microscopic polyarteritis’ versus ‘microscopic poly-
angiitis’ in the titles of papers published in the medical lit-
erature before and after the recommendation of the CHCC
to use the latter term.
One of the modifications that is anticipated in the 2011
CHCC nomenclature is a recommended change from the
diagnostic term ‘Wegner’s granulomatosis’ to ‘granulomato-
sis with polyangiitis’ (GPA), which has already been advo-
cated by some of the 2011 CHCC participants [1,2]. This is
justified both on the general rule that diagnostic terms with
eponyms are less effective than more descriptive terms that
refer to one or more distinctive features of a disease and, in
the specific instance of Wegener’s granulomatosis, on the
evidence that Dr Friedrich Wegener was a member of the
Nazi party before and during World War II [4].
The history of the naming of GPA (WG) is illustrative of
how a name can influence the understanding of a disease.
Instead of ‘rhinogenic granulomatosis’ [5], what if Wegener
had used the term ‘rhinogenic purulosis’, emphasizing the
intense purulent inflammation that is much more conspicu-
ous than true granulomatous inflammation in most acute
respiratory tract lesions of GPA (WG) (Fig. 1)? [6,7] Would
this emphasis on neutrophilic inflammation in the name
have drawn the attention of investigators sooner to the role
of neutrophils in the pathogenesis of GPA (WG)?
A granuloma (or granulomatous inflammation) is a lesion
characterized histologically by a compact accumulation of
predominantly macrophages that, if large enough, grossly
appears nodular. Giant cells, which are formed by the
coalescence of monocytes and macrophages into multi-
nucleated syncytia, may be a component of granulomas, but
giant cells are neither sufficient nor required for a diagnosis
of granulomatous inflammation. In the most literal sense,
granulomatosis indicates a condition characterized by mul-
tiple granulomas. Sarcoidosis is an archetype granulomato-
sis, although the term granulomatosis is rarely used in
discussing or writing about sarcoidosis. In fact, the term
granulomatosis is most often used in the medical literature
in the context of GPA (WG).
Especially in the acute lesions of GPA (WG), the predomi-
nant pattern of inflammation is not granulomatous, but
purulent. Thus, the inflammation has the appearance of an
abscess more than a granuloma (Fig. 2). Often, the only
feature in the acute inflammatory lesions that is reminiscent
of granulomatous inflammation is the presence of scattered
multi-nucleated giant cells. As lesions age, they often develop
a central zone of necrosis that seems to evolve from extensive
karyorrhectic (leucocytoclastic) debris to a central zone with
a slightly basophilic hue, and finally to a central zone of
amorphous acidophilic material (Fig. 3). Concurrent with
this degeneration of the central zone of neutrophils, the
periphery of the lesion accrues palisades of elongated mac-
rophages and scattered multi-nucleated giant cells that justify
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Fig. 1. Frequency of the use of the term ‘microscopic polyarteritis’
versus ‘microscopic polyangiitis’ in the title of articles in PubMed from
1990 to 2010. Graph (a) expresses this as the total number of articles
published per year. Graph (b) expresses this as a percentage of all
articles that had either term in the title. Note the change in usage after
publication of the recommendations of the Chapel Hill Consensus
Conference (CHCC) in 1994.
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being called granulomatous inflammation. Mark et al. [6]
concluded that in GPA (WG): ‘Micronecrosis, usually with
neutrophils (microabscesses), constitutes the early phase in
the development of the pathognomonic organized palisading
granuloma.’ They suggested that the multi-nucleated giant
cells might be a secondary reactive response to the acute
necrotizing lesions. This is supported by the finding of
engulfed apoptotic and necrotic neutrophil debris that can be
seen occasionally within the multi-nucleated giant cells at
sites of necrotizing inflammation in GPA (WG) (Fig. 2b).
This prominence of neutrophilic infiltrates (microab-
scesses) in the acute phase of the disease and the atypicality
of the granulomatous inflammation that follows have been
reported in detail in the literature [6,7] but probably, in part
because of the term ‘granulomatosis’ in the name, concepts
and theories about the pathogenesis of the extravascular
inflammation in GPA (WG) have drawn analogies to typical
granulomatous inflammation as seen in sarcoidosis or tuber-
culosis, which has little or no resemblance to the granulo-
matosis of GPA (WG). In a careful pathological study of
pulmonary specimens from 35 patients with GPA (WG),
Mark et al. [6] concluded that: ‘Compact granulomas of
tuberculoid or sarcoidal type did not occur in the cases of
Wegener’s granulomatosis.’
Although I have been concentrating on the neutrophilic
inflammation that is present during the acute phase of the
necrotizing inflammation, a distinctive type of multi-focal
granulomatous inflammation is unquestionably a hallmark
of GPA (WG), and may be the only pattern of inflammation
seen with treated chronic disease. This pattern of injury is
characterized by an irregular central zone of necrosis con-
taining varying numbers of degenerating neutrophils and
necrotic debris surrounded by poorly defined granuloma-
tous inflammation with palisades of elongated macrophages
and scattered multi-nucleated giant cells. This pattern of
injury with central necrosis and peripheral palisading mac-
rophages was well described in the seminal publications by
Wegener [5] and later by Godman and Churg [8]. Some
investigators have even concluded that this is essentially
pathognomonic for GPA (WG). For example, Mark et al. [6]
stated that: ‘Palisading granuloma is virtually pathogno-
(a)
(b)
Fig. 2. Photomicrographs of an acute necrotizing lesion in the lung of
a patient with granulomatosis with polyangiitis (GPA) (Wegener’s
granulomatosis) showing a central zone of necrosis with intense
influx of neutrophils (microabscess formation) with an adjacent
multi-nucleated giant cell: arrow in (a). The higher magnification in
(b) reveals a phagocytosed neutrophil (small arrow) and phagocytosed
apoptotic debris (large arrow) in the cytoplasm of a multi-nucleated
giant cell (haematoxylin and eosin stain).
Fig. 3. Photomicrographs of the edge of a necrotizing lesion in the
lung of a patient with granulomatosis with polyangiitis (GPA)
(Wegener’s granulomatosis) showing a zone of necrosis in the lower
right with a marginal band of palisading elongated macrophages
(arrows) in the upper left (haematoxylin and eosin stain).
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monic of Wegener’s granulomatosis whether or not it
involves blood vessels.’ They go on to note that: ‘Compact
granulomas of tuberculoid or sarcoidal type did not occur in
the cases of Wegener’s granulomatosis’. They contend that
there is a very distinctive special form of granulomatous
inflammation in patients with GPA (WG), but it is very
different from more typical forms of granulomatous
inflammation.
Thus, the pathology of GPA (WG) warrants using the
term granulomatosis in the name. As importantly, historical
precedent also supports the use of the term granulomatosis
in any new name for Wegener’s granulomatosis. As noted
earlier, granulomatosis has been used in the modern medi-
cal literature primarily in the context of Wegener’s
granulomatosis. Wegener initially used the term ‘rhinogenic
granulomatosis’ for this disease. Further, Churg and Strauss
used the term ‘allergic granulomatosis’ for what is often
called Churg–Strauss syndrome [9], which is related closely
to GPA (WG) and shares pathologically similar granuloma-
tosis, polyangiitis and glomerulonephritis with GPA (WG).
Microscopic polyangiitis (MPA) shares a systemic small
vessel vasculitis and pauci-immune necrotizing and crescen-
tic glomerulonephritis with GPA (WG) and allergic granu-
lomatosis (Churg–Strauss syndrome). All three diseases are
also associated with anti-neutrophil cytoplasmic autoanti-
bodies (ANCA), which appear to have a pathogenic role in
these diseases. This substantiates the hypothesis made by
Godman and Churg in 1954, based on pathology alone, that
these three diseases are closely related and probably share a
common pathogenic mechanism [8].
Another issue that will be addressed by the 2011 CHCC is
the role, if any, for ANCA serology in the diagnostic terms for
GPA (WG), MPA and allergic granulomatosis (Churg–
Strauss syndrome). For example, should this group (class) of
vasculitides be called ANCA disease or ANCA-associated
vasculitis, and should each clinicopathological variant name
be prefixed by MPO-ANCA, PR3-ANCA or ‘seronegative’
(e.g. PR3-ANCA GPA, MPO-ANCA MPA, seronegative
GPA, etc.)? There are clinical and pathophysiological argu-
ments in favour [1,10] and against [10] this approach.
One thing is certain: as our understanding of the clinical
manifestations, pathogenesis and aetiology of these and other
vasculitides change over time, the names and approaches for
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